Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
Browne BC, Eustace AJ, Kennedy S, O'Brien NA, Pedersen K, McDermott MS, Larkin A, Ballot J, Mahgoub T, Sclafani F, Madden S, Kennedy J, Duffy MJ, Crown J, O'Donovan N. Browne BC, et al. Among authors: sclafani f. Breast Cancer Res Treat. 2012 Dec;136(3):717-27. doi: 10.1007/s10549-012-2260-9. Epub 2012 Nov 2. Breast Cancer Res Treat. 2012. PMID: 23117852
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.
Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frodin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Watkins DJ. Sclafani F, et al. Int J Cancer. 2017 Jan 15;140(2):431-439. doi: 10.1002/ijc.30453. Epub 2016 Oct 17. Int J Cancer. 2017. PMID: 27681944 Clinical Trial.
New therapeutic targets in pancreatic cancer.
Lai E, Puzzoni M, Ziranu P, Pretta A, Impera V, Mariani S, Liscia N, Soro P, Musio F, Persano M, Donisi C, Tolu S, Balconi F, Pireddu A, Demurtas L, Pusceddu V, Camera S, Sclafani F, Scartozzi M. Lai E, et al. Among authors: sclafani f. Cancer Treat Rev. 2019 Dec;81:101926. doi: 10.1016/j.ctrv.2019.101926. Epub 2019 Nov 11. Cancer Treat Rev. 2019. PMID: 31739115 Review.
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.
Sclafani F, Roy A, Cunningham D, Wotherspoon A, Peckitt C, Gonzalez de Castro D, Tabernero J, Glimelius B, Cervantes A, Eltahir Z, Oates J, Chau I. Sclafani F, et al. Ann Oncol. 2013 Dec;24(12):3123-8. doi: 10.1093/annonc/mdt408. Epub 2013 Oct 20. Ann Oncol. 2013. PMID: 24146218 Free article. Clinical Trial.
FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic disease.
Sclafani F, Gonzalez de Castro D, Cunningham D, Hulkki Wilson S, Peckitt C, Capdevila J, Glimelius B, Roselló Keränen S, Wotherspoon A, Brown G, Tait D, Begum R, Thomas J, Oates J, Chau I. Sclafani F, et al. Clin Cancer Res. 2014 Sep 1;20(17):4511-9. doi: 10.1158/1078-0432.CCR-14-0674. Epub 2014 Jul 1. Clin Cancer Res. 2014. PMID: 24987061 Clinical Trial.
PD-1 and PD-L1 inhibitors in oesophago-gastric cancers.
Akin Telli T, Bregni G, Camera S, Deleporte A, Hendlisz A, Sclafani F. Akin Telli T, et al. Among authors: sclafani f. Cancer Lett. 2020 Jan 28;469:142-150. doi: 10.1016/j.canlet.2019.10.036. Epub 2019 Oct 25. Cancer Lett. 2020. PMID: 31669518 Review.
118 results